drugset / Trial / NCT00807261
Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Phase 2
Unknown
30 enrolled
Asan Medical Center
Korea University Anam Hospital · collabSamsung Medical Center · collabSeverance Hospital · collab
Non-randomizedSingle-groupOpen-labelSupportive care
Summary
To determine the activity of weekly Docetaxel and Gemcitabine in patients with advanced soft tissue sarcoma previously treated with anthracycline and/or ifosfamide 1. Primary endpoint: response rate 2. Secondary endpoint: progress-free survival, overall survival, safety
Timeline
- Start
- 2008-09
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 35 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |